AI Article Synopsis

  • Developing effective kinase inhibitors is difficult due to their tendency to bind non-specifically to the kinase hinge region.
  • A new class of compounds, 7,8-dichloro-1-oxo-β-carbolines, shows selective kinase inhibition without relying on typical ATP-like interactions.
  • These compounds display strong selectivity and low nanomolar activity against specific kinases, making them promising candidates for designing targeted therapies against various kinase-related diseases.

Article Abstract

Development of both potent and selective kinase inhibitors is a challenging task in modern drug discovery. The innate promiscuity of kinase inhibitors largely results from ATP-mimetic binding to the kinase hinge region. We present a novel class of substituted 7,8-dichloro-1-oxo-β-carbolines based on the distinct structural features of the alkaloid bauerine C whose kinase inhibitory activity does not rely on canonical ATP-mimetic hinge interactions. Intriguingly, cocrystal structures revealed an unexpected inverted binding mode and the presence of halogen bonds with kinase backbone residues. The compounds exhibit excellent selectivity over a comprehensive panel of human protein kinases while inhibiting selected kinases such as the oncogenic PIM1 at low nanomolar concentrations. Together, our biochemical and structural data suggest that this scaffold may serve as a valuable template for the design and development of specific inhibitors of various kinases including the PIM family of kinases, CLKs, DAPK3 (ZIPK), BMP2K (BIKE), and others.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257585PMC
http://dx.doi.org/10.1021/jm201286zDOI Listing

Publication Analysis

Top Keywords

kinase inhibitors
12
development potent
8
potent selective
8
selective kinase
8
kinase
6
78-dichloro-1-oxo-β-carbolines versatile
4
versatile scaffold
4
scaffold development
4
inhibitors
4
inhibitors unusual
4

Similar Publications

Article Synopsis
  • RbpA is a critical protein for Mycobacterium tuberculosis growth, impacting transcription and antibiotic response, but its regulatory mechanisms are not fully understood.
  • Significant structural changes in RNA polymerase occur when it interacts with RbpA, revealing important amino acids for transcription regulation and dynamic behavior of the complex.
  • The study identifies potential ligands for RbpA's interaction site, laying the groundwork for future research on developing inhibitors that target RbpA's regulatory role in transcription.
View Article and Find Full Text PDF

Interleukin-34 (IL-34) was recently reported to be a new biomarker for atherosclerosis diseases, such as coronary artery disease and vascular dementia. IL-34 regulates the expression of proinflammatory cytokines (IL-17A, IL-1 and IL-6), which are classical cytokines involved in myocardial ischemia‒reperfusion (MI/R) injury. However, the exact role of IL-34 in MI/R remains unknown.

View Article and Find Full Text PDF

Discoidin domain receptors (DDR) are categorized under tyrosine kinase receptors (RTKs) and play a crucial role in various etiological conditions such as cancer, fibrosis, atherosclerosis, osteoarthritis, and inflammatory diseases. The structural domain rearrangement of DDR1 and DDR2 involved six domains of interest namely N-terminal DS, DS-like, intracellular juxtamembrane, transmembrane juxtamembrane, extracellular juxtamembrane intracellular kinase domain, and the tail portion contains small C-tail linkage. DDR has not been explored to a wide extent to be declared as a prime target for any particular pathological condition.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) combined with anti-vascular endothelial growth factor (VEGF) have been the standard first-line treatment of hepatocellular carcinoma (HCC). However, the efficacy of this combination in post-line treatment is still unknown. This study aimed to evaluate the efficacy and safety of the combination of anti-PD-L1 envafolimab and novel humanized anti-VEGF suvemcitug as second-line treatment for patients with HCC.

View Article and Find Full Text PDF

Alpelisib is a phosphatidylinositol 3-kinase inhibitor approved by the US Food and Drug Administration for the treatment of hormone receptor-positive metastatic breast cancer with (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α) mutation. In recent years a number of adverse effects have been observed to be associated with this therapy, the most notable of which is hyperglycemia. A literature search was conducted to include case studies, case series, systematic reviews, and meta-analyses within the last 10 years that evaluated patients with mutated hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!